Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives.
about
Structural and functional perturbation of Giardia lamblia triosephosphate isomerase by modification of a non-catalytic, non-conserved regionHigh sensitivity of Giardia duodenalis to tetrahydrolipstatin (orlistat) in vitroEfficacy of 5-nitroimidazoles for the treatment of giardiasis: a systematic review of randomized controlled trialsIdentification and Validation of Small-Gatekeeper Kinases as Drug Targets in Giardia lambliaDeconjugated Bile Salts Produced by Extracellular Bile-Salt Hydrolase-Like Activities from the Probiotic Lactobacillus johnsonii La1 Inhibit Giardia duodenalis In vitro GrowthIdentification of intracellular and plasma membrane calcium channel homologues in pathogenic parasites.Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.Time-Dependent Transcriptional Changes in Axenic Giardia duodenalis TrophozoitesGiardia fatty acyl-CoA synthetases as potential drug targetsInhibitors of methionyl-tRNA synthetase have potent activity against Giardia intestinalis trophozoites.Microbiological and Pharmacological Evaluation of the Micropropagated Rubus liebmannii Medicinal Plant.Click Chemistry-Facilitated Structural Diversification of Nitrothiazoles, Nitrofurans, and Nitropyrroles Enhances Antimicrobial Activity against Giardia lamblia.Comparative characterisation of two nitroreductases from Giardia lamblia as potential activators of nitro compounds.Barcoding of Giardia duodenalis isolates and derived lines from an established cryobank by a mutation scanning-based approachCurrent treatment options for Dientamoeba fragilis infections.Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis.Management of acute infectious diarrhea for children living in resource-limited settings.Management of chronic Giardia infection.Antimicrobial therapy of acute diarrhoea: a clinical review.Antigiardial Activity of Podophyllotoxin-Type Lignans from Bursera fagaroides var. fagaroides.Use of Translation Blocking Morpholinos for Gene Knockdown in Giardia lamblia.Treatment of giardiasis: current status and future directions.[Gastrointestinal infections].The FAD-dependent glycerol-3-phosphate dehydrogenase of Giardia duodenalis: an unconventional enzyme that interacts with the g14-3-3 and it is a target of the antitumoral compound NBDHEX.Novel giardicidal compounds bearing proton pump inhibitor scaffold proceeding through triosephosphate isomerase inactivation.Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lambliaAntiprotozoal and Antimycobacterial Activities of Pure Compounds from Aristolochia elegans Rhizomes.Paediatrician and Caregiver Awareness of Cryptosporidiosis and Giardiasis in Children: US Survey Responses.Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia: characterization of a novel nitroreductase (GlNR2).Quinacrine pretreatment reduces microwave-induced neuronal damage by stabilizing the cell membrane.
P2860
Q27679239-EB9D1E2D-0917-40EF-B5E3-9A615DDFB186Q28535443-89BF7CA1-5C24-4D1C-808F-8A644D5AF648Q28540809-1536C911-9DE6-44C7-AA61-0B725C47FD1DQ28553158-416E4E92-89E1-4245-855B-F38DD312B736Q30815296-BFE2EAA7-AB28-4118-A571-A697354A34F6Q34056171-A097C6C3-70B7-4C4B-8EA5-AE91B638C8B9Q35189546-F161451C-5445-40BB-ADC8-2F5442BA3EAAQ35860807-115379BE-A058-454A-8098-41906993AEF6Q35877105-1CABB97F-4D60-4DD9-817A-448C022B8479Q36158335-1EA77164-7C19-47A7-AD5A-045325FA87AFQ36206639-3F390092-1A3E-4F2A-9884-EFAA52DBF74AQ36342610-6EDCD122-45C0-4A03-BD6D-6341C64664C4Q36745310-67D5D589-9B30-4CE0-B4CF-D1E60B204BC2Q37260581-D5D53306-1E7F-4545-AFE4-339CC5CAC4DAQ37390538-B8ADA06D-ECD5-4596-8D1F-F04EC42115CEQ37734423-85BE25E2-C524-4F0B-80FB-8D90AE5A4812Q38198766-F782E6A7-E3A4-47F3-885C-495BF65C54AAQ38233620-326C6071-47E2-4D3F-BE7D-F11DF36CB553Q38660838-A924894A-E834-4694-AD17-7F69856D6491Q38703511-843B188B-15C4-46CE-A886-FAEF1EF3005BQ38863727-9D844E85-4CE1-46FA-80E6-D6075EEF74BBQ39257022-693EB1EC-C571-449D-B869-E677DC1C17C4Q40072061-2DE13943-92CC-4F11-98C8-6F3ABD57BF5BQ41155805-6E3C4CD8-38CC-4020-A85C-D133B7D1A74FQ41352700-6549B9D1-D1C3-49DF-8B89-C2C2F855DF4EQ42116901-F1B69302-B287-426E-8AD0-86B637FCEBEBQ42612800-791310AA-9008-407C-A13E-B24C5FBB933DQ43176221-332F9B1A-74A3-44F0-BBF1-0F7F53DA9EADQ45219788-840DD553-DA6D-43B3-902B-CCB4EEA39639Q55387592-3E67F388-1091-466A-ACB6-6BE260A316BD
P2860
Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Giardiasis in the post genomic ...... ovel therapeutic perspectives.
@en
Giardiasis in the post genomic ...... ovel therapeutic perspectives.
@nl
type
label
Giardiasis in the post genomic ...... ovel therapeutic perspectives.
@en
Giardiasis in the post genomic ...... ovel therapeutic perspectives.
@nl
prefLabel
Giardiasis in the post genomic ...... ovel therapeutic perspectives.
@en
Giardiasis in the post genomic ...... ovel therapeutic perspectives.
@nl
P1476
Giardiasis in the post genomic ...... ovel therapeutic perspectives.
@en
P2093
Marco Lalle
P304
P356
10.2174/187152610791591610
P577
2010-08-01T00:00:00Z